Normal
ASX: PTX - Undervalued Biotech Expected to Complete Three Clinical Trials in 2016 PrPrescient Therapeutics (“PTX,” “Prescient,” or the “Company”) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front-line chemotherapy. The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth across a variety of cancers including breast, ovarian, leukemia, and multiple myeloma. PTX is currently in a Phase Ib/II trial for breast cancer (partially funded by the U.S. Department of Defense), a Phase Ib trial for ovarian cancer (partially funded by the National Cancer Institute), and expects to initiate a Phase Ib trial for Acute Myeloid Leukemia (AML) in early 2016. The Company’s science/IP comes from Yale University and Moffitt Cancer Center.
ASX: PTX - Undervalued Biotech Expected to Complete Three Clinical Trials in 2016 Pr
Prescient Therapeutics (“PTX,” “Prescient,” or the “Company”) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front-line chemotherapy. The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth across a variety of cancers including breast, ovarian, leukemia, and multiple myeloma. PTX is currently in a Phase Ib/II trial for breast cancer (partially funded by the U.S. Department of Defense), a Phase Ib trial for ovarian cancer (partially funded by the National Cancer Institute), and expects to initiate a Phase Ib trial for Acute Myeloid Leukemia (AML) in early 2016. The Company’s science/IP comes from Yale University and Moffitt Cancer Center.
Hello and welcome to Aussie Stock Forums!
To gain full access you must register. Registration is free and takes only a few seconds to complete.
Already a member? Log in here.
